Skip to main content
David Harlan, MD, Endocrinology, Worcester, MA

DavidMarshallHarlanMD

Endocrinology • Worcester, MA

Diabetes, Lipid Metabolism

Professor of Medicine, University Mass School of Medicine

Join to view full profile

Dr. Harlan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Harlan's full profile

Already have an account?

  • Office

    55 Lake Ave N
    # Ambulato
    Worcester, MA 01655
    Phone+1 508-334-3206
    Fax+1 508-856-3811

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 1988 - 1989
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1981 - 1984
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1980

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2009 - 2024
  • CA State Medical License
    CA State Medical License 1985 - 2022
  • NC State Medical License
    NC State Medical License 1983 - 2009
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
  • Elected Member The American Society for Clinical Investigation, 2001

Publications & Presentations

PubMed

Lectures

  • 2013 Rachmiel Levine Diabetes and Obesity Symposium 
    City of Hope, Pasadena, California - 3/13/2013
  • 12th Annual Rachmiel Levine Diabetes & Obesity Symposium: Advances in Diabetes Research 
    City of Hope, Pasadena, California - 2/15/2012
  • Molecular Profiling of Human Pancreatic Alpha and Beta Cells in Health and Disease 
    Worcester, MA - 6/15/2014

Press Mentions

  • First Patient-Derived Stem Cell Transplant a Success in T1D
    First Patient-Derived Stem Cell Transplant a Success in T1DOctober 3rd, 2024
  • FDA Panel Supports Islet Cell Treatment for Type 1 Diabetes
    FDA Panel Supports Islet Cell Treatment for Type 1 DiabetesApril 16th, 2021
  • Researchers Gain Insights into Cellular Processes Associated with Diabetes
    Researchers Gain Insights into Cellular Processes Associated with DiabetesMay 3rd, 2019
  • Join now to see all

Grant Support

  • Molecular Mechanisms Underlying NHP Pancreatic Beta Cell Failure, And RecoveryNational Institute Of Diabetes And Digestive And Kidney Diseases2011
  • Molecular Mechanisms Of Human And Murine Beta Cell Proliferation And RegenerationNational Institute Of Diabetes And Digestive And Kidney Diseases2010–2011
  • Transplant-Based Treatment Approaches For T1dmNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
  • Rodent Pancreatic Islet Biology In Health And DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
  • Preclinical Studies For Measuring Beta Cell Mass In VivoNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
  • Novel Techniques For Assessing Beta Cell TurnoverNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
  • Mouse Model To Assess Putative Beta Cell Progenitor CellsNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
  • Inpatient And Outpatient Infrastructure For T1dm Clinical ProtocolsNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
  • Immunological Mechanisms Underlying T1dm PathogenesisNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
  • Secondary Prevention Trials For Recently Diagnosed Type 1 Diabetes MellitusNational Institute Of Diabetes And Digestive And Kidney Diseases2009
  • Diabetes Endocrinology Research Center (DERC)National Institute Of Diabetes And Digestive And Kidney Diseases2009
  • Assessing A Pet-Based Technique For Characterizing Beta Cell Mass In VivoNational Institute Of Diabetes And Digestive And Kidney Diseases2009
  • 03-Dk-0245 (Effect Of Ac2993 (Synthetic Exendin-4) On Pancreatic Islet Function)National Institute Of Diabetes And Digestive And Kidney Diseases2009
  • Transplant-Based Treatment Approaches For T1dmNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2008
  • Rodent Pancreatic Islet Biology In Health And DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2008
  • Preclinical Studies For Measuring Beta Cell Mass In VivoNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2008
  • Novel Techniques For Assessing Beta Cell TurnoverNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2008
  • Mouse Model To Assess Putative Beta Cell Progenitor CellsNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2008
  • Inpatient And Outpatient Infrastructure For T1dm Clinical ProtocolsNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2008
  • 03-Dk-0245 (Effect Of Ac2993 (Synthetic Exendin-4) On Pancreatic Islet Function)National Institute Of Diabetes And Digestive And Kidney Diseases2007–2008
  • Islet Cell Transplantation For T1DM: Clinical Studies AnNational Institute Of Diabetes And Digestive And Kidney Diseases2006
  • Islet Cell Transplantation For T1dm--Clinical StudiesNational Institute Of Diabetes And Digestive And Kidney Diseases2005
  • Islet Cell Transplantation For T1DM: Clinical StudiesNational Institute Of Diabetes And Digestive And Kidney Diseases2004

Dr. David Harlan, Dr. David Harlan, MD, Dr. D Harlan, Dr. David Marshall Harlan